Quick answer
What is Liraglutide?
Built from index records dated 2026-10-09 to 2026-10-13 Compiled by an automated pipeline, checked by The Peptide Observer editorial desk. No qualified clinical reviewer. How this site works
Liraglutide is a peptide, grouped on this site under Incretin receptor agonists, and the 12 research records kept here are 1 from a study in rats or mice and 11 from trials in people.
The literature search returned 5,673 records. This site keeps 12 of them, which is 0.21 per cent of what came back.
What it is
This site puts it in the Incretin receptor agonists group.
Agonist at the glucagon-like peptide-1 receptor.[1, 2] (derived value: Derived: the receptor mechanism is taken from the cited 2024 GLP-1 receptor review, and this compound is placed in that class by the cited 2024 BMJ network meta-analysis of GLP-1 receptor agonists. No retrieved title for this compound states the receptor directly.)
Derived: the receptor mechanism is taken from the cited 2024 GLP-1 receptor review, and this compound is placed in that class by the cited 2024 BMJ network meta-analysis of GLP-1 receptor agonists. No retrieved title for this compound states the receptor directly.
What kind of records
Several of the records kept here are trials in people.
That sentence is produced by counting, not by reading. What was counted: 11 of 12 indexed records are interventional human trials by their own assigned publication type.
What this does not settle
- What it does in a body. Counting records is not reading them, and nothing here has been read in full.
- Whether it causes harm. No adverse-effect row was taken from any source for this entry.
- How long it lasts. No pharmacokinetics source was retrieved for this entry.
- What the other 5,661 retrieved records say. They are not in this index.
The longer explanation
Where this comes from
The records cited above, in full.
- Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduct Target Ther (2024). pmid:39289339
- Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. BMJ (2024). pmid:38286487